Symptomatic Epstein-Barr virus reactivation in a patient with acute myeloid leukaemia and treatment with the monoclonal anti-CD20 antibody rituximab.
In a patient with acute myeloid leukaemia, treated with several courses of chemotherapy including a fludarabine-containing regimen, severe symptoms due to Epstein-Barr virus reactivation occurred but could be successfully treated with the monoclonal anti-CD20 antibody rituximab. Depletion of viral host cells may be effective in treatment of symptoms due to Epstein-Barr virus reactivation.
Tinchon
Christoph
C
Division of Haematology, Department of Medicine, Karl-Franzens University Graz, Austria. christoph.tinchon@uni-graz.ac.at
Auner
Holger W
HW
Beham-Schmid
Christine
C
Aberle
Stephan W
SW
Sill
Heinz
H
Linkesch
Werner
W
D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004854:Herpesvirus 4, Human / Q000302:isolation & purification* / Q000502:physiology; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D008212:Lymphocyte Depletion; D008297:Male; D000069283:Rituximab; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab